SynthesisFrontiers in medicine2026
Global landscape and emerging trends in programmable mRNA-based therapeutics for myocardial infarction: a multi-database bibliometric analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myocardial infarction (MI) remains a leading cause of mortality worldwide. Although current reperfusion-based interventions have significantly improved clinical outcomes, they are insufficient to restore lost cardiomyocytes or repair irreversible myocardial injury. Programmable messenger RNA (mRNA)-based therapeutics have emerged as a cutting-edge strategy for cardiac regenerative repair owing to their advantages of transient and controllable protein expression, high design flexibility, and avoidance of genomic integration. However, the global research landscape, collaborative networks, and evolving scientific priorities in this rapidly expanding field have not yet been systematically characterized. Methods: A comprehensive bibliometric analysis was conducted using publications retrieved from the Web of Science Core Collection (WoSCC) and PubMed databases from 2012 to 2026. After literature screening and deduplication, 814 publications from WoSCC and 4,155 publications from PubMed were included. VOSviewer, CiteSpace, and the R package Bibliometrix were used to conduct parallel analyses of annual publication trends, country- and institutional-collaboration networks, journal and author distributions, reference citation bursts, and keyword-based thematic evolution. Results: WoSCC analysis revealed a fluctuating but overall increasing publication trajectory, with annual research output peaking at ∼90 publications in 2023. The evolution of this field could be categorized into three stages: an emerging phase (2012-2016), a developmental phase (2017-2021), and an accelerated expansion phase (2022 onward). China and the United States represented the leading contributors, while institutions including Harvard University and the Chinese Academy of Medical Sciences-Peking Union Medical College served as major research hubs. Circulation Research and Circulation occupied central positions within the co-citation network. ZANG, LICHUN was identified as the most productive author, whereas the landmark 2013 study by Zangi L represented the most influential foundational contribution to the field. Parallel analysis of PubMed further validated the identified evolutionary trends and highlighted angiogenesis as a promising yet underexplored research direction. Conclusion: Research on programmable mRNA therapeutics for MI is rapidly expanding, with the focus shifting from fundamental molecular mechanisms to translational applications that enable precise inflammatory modulation, fibrosis reversal, and revascularization. Future breakthroughs will likely depend on the development of efficient and cardiac-targeted delivery platforms, as well as deeper exploration of epitranscriptomic therapeutic strategies, to accelerate clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.